HOME >> BIOLOGY >> NEWS
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of 64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses. The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better (P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients wi
'"/>

Contact: Prof Per Hall
per.hall@ki.se
46-73-625-0342
Karolinska Institutet
2-Oct-2005


Page: 1 2

Related biology news :

1. The Center of Nutrigenomics of the TU Munich licences Genomatix Microarray Analysis Pipeline
2. German Microarray Excellence Center integrates Genomatix Chip Analysis Pipeline
3. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible status
4. Microarrays as phenotype
5. AFCYBER holds science and technology symposium
6. New technology reveals seal behavior
7. Nanotechnology helps scientists make bendy sensors for hydrogen vehicles
8. FDA Nanotechnology Task Force takes positive step forward
9. Liverpool amongst first in UK to install unique DNA sequencing technology
10. EPA foregoes opportunity to improve nanotechnology oversight
11. The Cancer Genome Atlas awards funds for technology development

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... 2017 In today,s pre-market research, ... Intrexon Corp. (NYSE: XON), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), ... According an article on Barron,s, Credit Suisse upgraded its rating ... March 21 st , 2017. These stocks research reports can ... ...
(Date:3/29/2017)... Pa. , March 29, 2017 Patients ... which is why CSL Behring awards Local Empowerment for ... rare disease patient groups. These groups tackle complex legislative ... heard on Capitol Hill and in statehouses across the ... the community-based grant was awarded to New England Hemophilia ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Last year,s petition ... are not the only efforts active to generate awareness on the ... based pharmaceutical drugs in the healthcare market place. ... Earlier this month Health ... and distributor of pharmaceutical and nutritional products, announced its endeavors on ...
(Date:3/29/2017)... Alto, CA, USA (PRWEB) , ... March 29, 2017 , ... ... in various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 venue ... at the Omni Parker House Hotel, in Boston, MA. , The Omni Parker House ...
Breaking Biology Technology:
Cached News: